Ignite Creation Date:
2024-10-26 @ 3:36 PM
Last Modification Date:
2024-10-26 @ 3:36 PM
Study NCT ID:
NCT06530004
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-06-14
Brief Title:
Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This was a retrospective study Children who were diagnosed with refractory nephrotic syndrome and treated with rituximab RTX and followed up for 1 year in the Department of Pediatrics the First Affiliated Hospital of Xiamen University from March 2020 to March 2026 were enrolled Personal information past medical history clinical examination data and follow-up data before and after the use of RTX were extracted from the medical record system 1 The median relapse-free survival the number of relapses and the adverse reactions of RTX were compared before and after RTX treatment and the clinical efficacy and safety of RTX were evaluated 2 By comparing the annual relapse frequency reduction and withdrawal of steroids and immunosuppressive agents B cell reconstitution and adverse drug reactions between prophylactic RTX and post-relapse RTX maintenance regimens 3 Multivariate analysis of risk factors for recurrence of nephropathy after RTX treatment 4 growth indicators monitoring patient evaluation and RTX medical economic benefit analysis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None